After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
An update on some recent small biotech recommendations.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.